Tag:

AMRI

Latest Headlines

Latest Headlines

Manufacturing moves pay off for AMRI

Contract manufacturer AMRI has been reworking its manufacturing assets, picking up valuable pieces here and there and then sacrificing a less important one as it moves toward contract manufacturing and away from a reliance on royalties. Its most recent earnings suggest the strategy is paying off on the top line at least.

AMRI swings to another loss despite big sales gains

Contract drug developer AMRI, on the mend after a series of setbacks, posted a 38% sales boost to start the year, but the costs of an ongoing transition dragged it into the red for yet another quarter.

AMRI shutters another plant with an eye on its bottom line

Contract drug developer AMRI is closing down a U.K. manufacturing operation as part of its across-the-board change in strategy, an effort to get back to growth after a rough string of quarters.

AMRI moves forward with plan to close Wales API plant, cut 62 jobs

U.S. contract manufacturer AMRI says that it will follow through with plans to close its API manufacturing site in Holywell, U.K., a move that will mean the loss of 62 jobs.

AMRI plans to close plant in Wales

Sixty-four jobs are at risk as a result of AMRI's proposal to close an API plant in Wales. A final decision for the plant will come after a consultation with employees and discussions on ways to reduce "redundancies" at the former Excelsyn facility.

AMRI posts a net quarterly loss in the midst of a realignment

Marred by bad weather and an ongoing transition, contract drug developer AMRI swung to a loss in the fourth quarter, but steady gains in revenue have the company optimistic about the coming year.

AMRI inks a 10-year NIH deal with $37M on the line

In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.

AMRI buys more manufacturing capacity with deal for two Aptuit facilities

AMRI has extended a buying streak to build up its contract manufacturing capabilities, adding to its injectable drug operations in the process. The New York-based company will lay out $60 million to buy two facilities from drug development specialist Aptuit.

AMRI spends $60M to beef up its manufacturing heft

AMRI, on the mend after a rough quarter, is laying out $60 million to expand its manufacturing footprint, agreeing to buy a couple of outposts from service provider Aptuit.

AMRI gets its desert branch back online after a profit-sapping outage

After a weather-related shutdown at a New Mexico facility helped tank its quarterly earnings, AMRI has rectified the issue, bringing its plant back online as it works to get back on the path to growth.